Article Information
History
- January 31, 2024.
Copyright
The copyright holder has placed this preprint in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse, remix, or adapt this material for any purpose without crediting the original authors.
Author Information
- Chunyan Zhanga,b,c,
- Jie Zhengd,
- Jin Liue,
- Guoqiang Xinga,
- Shupeng Zhanga,
- Hekai Chena,
- Jian Wanga,
- Zhijiang Shaoa,c,
- Yongyuan Lia,c,
- Zhongmin Jiangd,
- Yingzi Panf,
- Xiaozhi Liub,c,
- Ping Xuc,g,* and
- Wenhan Wua,b,c,h,**
- aDepartment of General Surgery, Tianjin Fifth Central Hospital, Tianjin, PR China
- bTianjin Key Laboratory of Epigenetics for Organ Development of Premature Infants, Tianjin Fifth Central Hospital, Tianjin, PR China
- cHigh Altitude Characteristic Medical Research Institute, Huangnan Tibetan Autonomous Prefecture People’s Hospital, Huangnan Prefecture, Qinghai, P.R. China
- dDepartment of Pathology, Tianjin Fifth Central Hospital, Tianjin, PR China
- eNorth China University of Science and Technology, Tangshan City, Hebei Province, PR China
- fDepartment of Ophthalmology, Peking University First Hospital, Beijing, PR China
- gDepartment of Pharmacy, Tianjin Fifth Central Hospital, Tianjin, PR China
- hDepartment of General Surgery, Peking University First Hospital, Beijing, PR China
Posted January 31, 2024.
Pan-cancer analyses reveal molecular and clinical characteristics of TET family members and suggests that TET3 maybe a potential therapeutic target
